Dr Reddy's Semaglutide: What the Evidence Says About Generic Semaglutide in the UK

What the STEP 1 trial actually established — and why the licensed product matters

The clinical case for semaglutide as a weight-management medicine rests on rigorous data. The STEP 1 trial, published in the New England Journal of Medicine, enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition and no type 2 diabetes. Over 68 weeks, those taking semaglutide 2.4 mg weekly alongside lifestyle changes lost an average of around 15% of body weight, compared with roughly 2.4% in the placebo group. That gap is substantial. The trial used Novo Nordisk's branded formulation at a specific dose and titration schedule, which is the version the MHRA assessed when granting Wegovy its UK marketing authorisation. A marketing authorisation is not a formality: it reflects a detailed review of a particular manufacturer's data on that exact product, including its purity, stability and delivery mechanism. Switching manufacturer changes that equation entirely, and the MHRA has not conducted that review for any Dr Reddy's semaglutide product for weight management in the UK. There is also the matter of what the NICE guidance on semaglutide actually recommends: the NICE technology appraisal TA875 covers Wegovy specifically, within a specialist weight management service framework, for a maximum of two years, and with defined BMI and comorbidity thresholds. Generic alternatives are simply outside that appraisal's scope.

Why Dr Reddy's semaglutide is appearing in UK searches

Dr Reddy's Laboratories is a well-established Indian generic pharmaceutical company that holds regulatory authorisations for semaglutide in certain markets. Its name began surfacing in UK searches partly because of the acute Wegovy shortage that ran from 2023 into 2025, which pushed some patients and clinicians to investigate every possible supply route. That shortage has now largely resolved for the licensed product. The curiosity is understandable; the clinical profile of semaglutide is genuinely impressive, and cost is a real concern for patients paying privately. But the MHRA has been unambiguous: injectable medicines sourced outside the licensed UK supply chain, including through online sellers without a prescription, pose documented safety risks. The agency has seized millions of fake weight-loss pens, some containing insulin at dangerous concentrations, and raided illicit manufacturing sites. The risk is not theoretical. If you encounter a seller offering Dr Reddy's semaglutide, or any semaglutide product, without requiring a prescription and clinical assessment, that is a significant red flag. The MHRA's Yellow Card scheme allows anyone to report suspect sellers, and the agency actively acts on those reports.

What legitimate semaglutide access looks like in the UK right now

For patients considering semaglutide for weight management, the licensed route is straightforward in structure, even if it requires some patience to navigate. Wegovy is available privately through GPhC-registered pharmacies following a prescription from a qualified independent prescriber. It is also available on the NHS, though under TA875 that route sits within specialist weight management services and waiting times can be long. The titration schedule begins at a low dose and rises over several months toward the 2.4 mg maintenance dose, and as of April 2026, the MHRA approved a 7.2 mg single-dose pen for adults with a BMI of 30 or above, which extends the dose ceiling further than the original licence allowed. If cost is weighing on your thinking, reading about how Wegovy pricing works in the UK may help frame expectations before you start. One practical note: a lot of patients time their first consultation around payday or the start of a new month, and that is entirely sensible, clinical assessments are available on working days, and ordering before noon means dispatch the same day once approved. There is nothing wrong with planning around your own schedule. A prescription for semaglutide is not awarded automatically by meeting a BMI threshold. Prescribers also consider your medical history, current medicines, and specific contraindications, including a history of medullary thyroid carcinoma or pancreatitis. Pregnancy, breastfeeding, and trying to conceive are also situations where semaglutide is not recommended. The assessment exists to protect you, not to create obstacles.

How the oral semaglutide approval adds a further layer to the picture

Alongside the injectable Wegovy, June 2026 brought a further development: the MHRA granted the first UK authorisation for an oral GLP-1 weight-management medicine, Wegovy tablets, also made by Novo Nordisk. This is a different product from Rybelsus, which is oral semaglutide licensed only for type 2 diabetes. The Wegovy tablet is licensed for adults with a BMI of 30 or above, or 27 to 29.9 with a weight-related condition, and its trial data showed an average weight reduction of around 13.6% over 64 weeks regardless of adherence. Among participants who adhered fully to treatment, that figure rose to around 17%. The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food or other medicines, and requires no refrigeration, making it notably more travel-friendly. You can read more about the full treatment landscape on the weight-loss treatments overview. The oral route does not change the regulatory picture for generic semaglutide: the Wegovy tablet is a Novo Nordisk product assessed by the MHRA under its own licence; a generic oral semaglutide for weight management does not exist in the UK. Any clinician reviewing your case through a consultation with our prescribers will consider both injection and tablet options and explain which might suit your circumstances. The starting-dose period is typically where most questions arise, and having a prescriber to contact directly during that phase matters more than people expect before they begin.